Cauda Equina Neuroendocrine Tumors Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin

被引:5
作者
Asa, Sylvia L. [1 ]
Mete, Ozgur [2 ]
Schueller, Ulrich [3 ]
Ramani, Biswarathan [4 ]
Mirchia, Kanish [4 ]
Perry, Arie [4 ]
机构
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Cleveland, OH USA
[2] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[3] Univ Hosp Hamburg, Hamburg, Germany
[4] Univ Calif San Francisco, San Francisco, CA USA
关键词
cauda equina; neuroendocrine tumor; paraganglioma; transcription factors; hormones; RECTAL NEUROENDOCRINE;
D O I
10.1097/PAS.0000000000002009
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The tumor formerly known as "cauda equina paraganglioma" was recently renamed as cauda equina neuroendocrine tumor (CENET) based on distinct biological and genetic properties. Nevertheless, it remains insufficiently understood. For this study, we retrieved CENETs (some previously reported), from the pathology files of 3 institutions; we examined their immunohistochemical profile, including common neuroendocrine tumor-associated hormones and transcription factors. We identified 24 CENETs from 7 female and 17 male adult patients, with a median age of 47 years. Six included neurofilament-positive ganglion cells. All tumors tested were positive for INSM1, synaptophysin, chromogranin A, SSTR2, and CD56 as well as at least 1 keratin (AE1/AE3, CAM5.2); CK7 and CK20 were negative. Glial fibrillary acidic protein was negative, except for peripheral nontumoral elements. S100 protein was variable but mainly expressed in scattered sustentacular cells. All but 1 tumor tested were positive for HOXB13; several stained for SATB2, and all tumors were consistently negative for GATA3. All tumors tested were negative for transcription factors found in various other epithelial neuroendocrine neoplasms including TTF1, CDX2, PIT1, TPIT, SF1, and PAX8; staining for T-brachyury was negative. Four of 5 CENETs tested had at least focal tyrosine hydroxylase reactivity. Serotonin expression was detected in all 21 tumors tested; it was diffusely positive in 5 and had variable positivity in the remainder. A few tumors had scattered cells expressing gastrin, calcitonin, pancreatic polypeptide, and peptide YY, while glucagon, adrenocorticotropic hormone, and monoclonal carcinoembryonic antigen were negative. PSAP expression was found focally in 4 of 5 tumors examined. SDHB was consistently intact; ATRX was intact in 14 tumors and showed only focal loss in 3. The median Ki-67 labeling index was 4.5% (range: 1% to 15%). We conclude that CENET represents a distinct neuroendocrine neoplasm; the subset with ganglion cells qualifies for designation as composite gangliocytoma/neuroma-neuroendocrine tumor (CoGNET) as defined in the 2022 WHO classification of neuroendocrine neoplasms. In addition to INSM1, chromogranin, synaptophysin, and keratins, the most characteristic finding is nuclear HOXB13 expression; a subset also express SATB2. Serotonin is the most common hormone expressed. The cytogenesis and pathogenesis of these lesions remains unclear.
引用
收藏
页码:469 / 475
页数:7
相关论文
共 29 条
  • [21] PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma
    Miyauchi, Minami
    Akashi, Takumi
    Furukawa, Asuka
    Uchida, Keisuke
    Tamura, Tomoki
    Ando, Noboru
    Kirimura, Susumu
    Shintaku, Hiroshi
    Yamamoto, Kurara
    Ito, Takashi
    Miura, Keiko
    Kayamori, Kou
    Ariizumi, Yosuke
    Asakage, Takahiro
    Kudo, Atsushi
    Tanabe, Minoru
    Fujii, Yasuhisa
    Ishibashi, Hironori
    Okubo, Kenichi
    Murakami, Masanori
    Yamada, Tetsuya
    Takemoto, Akira
    Bae, Yuan
    Eishi, Yoshinobu
    Ohashi, Kenichi
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (04) : 506 - 518
  • [22] Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes
    Nose, Vania
    Gill, Anthony
    Cameselle Teijeiro, Jose Manuel
    Perren, Aurel
    Erickson, Lori
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (01) : 197 - 227
  • [23] The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma
    Ramani, Biswarathan
    Gupta, Rohit
    Wu, Jasper
    Barreto, Jairo
    Bollen, Andrew W.
    Tihan, Tarik
    Mummaneni, Praveen V.
    Ames, Christopher
    Clark, Aaron
    Oberheim Bush, Nancy Ann
    Butowski, Nicholas
    Phillips, Daniel
    King, Bruce E.
    Bator, Susan M.
    Treynor, Elizabeth C.
    Zherebitskiy, Viktor
    Quinn, Paula S.
    Walker, Jeffrey B.
    Pekmezci, Melike
    Sullivan, Daniel V.
    Hofmann, Jeffrey W.
    Sloan, Emily A.
    M. Chang, Susan
    Berger, Mitchel S.
    Solomon, David A.
    Perry, Arie
    [J]. ACTA NEUROPATHOLOGICA, 2020, 140 (06) : 907 - 917
  • [24] Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
    Rindi, Guido
    Mete, Ozgur
    Uccella, Silvia
    Basturk, Olca
    La Rosa, Stefano
    Brosens, Lodewijk A. A.
    Ezzat, Shereen
    de Herder, Wouter W.
    Klimstra, David S.
    Papotti, Mauro
    Asa, Sylvia L.
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (01) : 115 - 154
  • [25] A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
    Rindi, Guido
    Klimstra, David S.
    Abedi-Ardekani, Behnoush
    Asa, Sylvia L.
    Bosman, Frederik T.
    Brambilla, Elisabeth
    Busam, Klaus J.
    de Krijger, Ronald R.
    Dietel, Manfred
    El-Naggar, Adel K.
    Fernandez-Cuesta, Lynnette
    Kloeppel, Guenter
    McCluggage, W. Glenn
    Moch, Holger
    Ohgaki, Hiroko
    Rakha, Emad A.
    Reed, Nicholas S.
    Rous, Brian A.
    Sasano, Hironobu
    Scarpa, Aldo
    Scoazec, Jean-Yves
    Travis, William D.
    Tallini, Giovanni
    Trouillas, Jacqueline
    van Krieken, J. Han
    Cree, Ian A.
    [J]. MODERN PATHOLOGY, 2018, 31 (12) : 1770 - 1786
  • [26] SalMar ASA,, 2020, HAVB FISK SALMAR ASA
  • [27] Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity
    Schweizer, Leonille
    Thierfelder, Felix
    Thomas, Christian
    Soschinski, Patrick
    Suwala, Abigail
    Stichel, Damian
    Wefers, Annika K.
    Wessels, Lars
    Misch, Martin
    Kim, Hee-yeong
    Joedicke, Ruben
    Teichmann, Daniel
    Kaul, David
    Kahn, Johannes
    Bockmayr, Michael
    Hasselblatt, Martin
    Younsi, Alexander
    Unterberg, Andreas
    Knie, Bettina
    Walter, Jan
    Al Safatli, Diaa
    May, Sven-Axel
    Joedicke, Andreas
    Ntoulias, Georgios
    Moskopp, Dag
    Vajkoczy, Peter
    Heppner, Frank L.
    Capper, David
    Hartmann, Wolfgang
    Hartmann, Christian
    von Deimling, Andreas
    Reuss, David E.
    Schoeler, Anne
    Koch, Arend
    [J]. ACTA NEUROPATHOLOGICA, 2020, 140 (06) : 893 - 906
  • [28] Sohn JH, 2015, CANCER RES TREAT, V47, P813
  • [29] Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
    Vujovic, S.
    Henderson, S.
    Presneau, N.
    Odell, E.
    Jacques, T. S.
    Tirabosco, R.
    Boshoff, C.
    Flanagan, A. M.
    [J]. JOURNAL OF PATHOLOGY, 2006, 209 (02) : 157 - 165